Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $1.91 $2.42 Friday, 10th May 2024 CANF stock ended at $2.09. This is 2.42% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 3.29% from a day low at $2.05 to a day high of $2.12.
90 days $1.91 $2.71
52 weeks $1.81 $3.33

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Sep 15, 2016 $2.40 $2.40 $2.22 $2.28 25 700
Sep 14, 2016 $2.39 $2.41 $2.27 $2.28 94 400
Sep 13, 2016 $2.42 $2.49 $2.36 $2.36 55 100
Sep 12, 2016 $2.30 $2.45 $2.30 $2.38 40 600
Sep 09, 2016 $2.32 $2.39 $2.30 $2.35 46 000
Sep 08, 2016 $2.52 $2.52 $2.35 $2.39 43 900
Sep 07, 2016 $2.42 $2.55 $2.42 $2.51 84 200
Sep 06, 2016 $2.42 $2.47 $2.39 $2.43 83 200
Sep 02, 2016 $2.57 $2.57 $2.30 $2.36 189 700
Sep 01, 2016 $2.47 $2.50 $2.42 $2.47 65 300
Aug 31, 2016 $2.66 $2.66 $2.47 $2.48 116 100
Aug 30, 2016 $2.50 $2.65 $2.38 $2.61 278 000
Aug 29, 2016 $2.57 $2.57 $2.34 $2.50 515 600
Aug 26, 2016 $2.40 $2.41 $2.31 $2.40 45 500
Aug 25, 2016 $2.45 $2.50 $2.34 $2.37 60 800
Aug 24, 2016 $2.35 $2.55 $2.33 $2.46 225 500
Aug 23, 2016 $2.49 $2.49 $2.30 $2.37 82 500
Aug 22, 2016 $2.20 $2.53 $2.20 $2.44 439 900
Aug 19, 2016 $2.24 $2.26 $2.21 $2.23 11 600
Aug 18, 2016 $2.22 $2.28 $2.21 $2.25 20 200
Aug 17, 2016 $2.19 $2.29 $2.19 $2.22 27 900
Aug 16, 2016 $2.23 $2.28 $2.20 $2.21 15 600
Aug 15, 2016 $2.19 $2.30 $2.19 $2.25 33 600
Aug 12, 2016 $2.20 $2.25 $2.19 $2.19 27 300
Aug 11, 2016 $2.16 $2.20 $2.15 $2.17 34 800
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT